HOWL Werewolf Therapeutics, Inc.
Healthcare$0.44+5.02%ClosedMarket Cap: $21.6M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
1.77
P/S
0.00
EV/EBITDA
-0.27
DCF Value
$1.02
FCF Yield
-240.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-208.2%
ROA
-97.0%
ROIC
-103.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-9.0M | $-13.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-9.4M | $-8.4M | $— | — |
| FY null | $0.00 | -Infinity% | $-60.7M | $-60.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-15.7M | $-16.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-17.5M | $-18.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-18.0M | $-18.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-20.3M | $-20.4M | $— | — |
| FY null | $1.9M | 3.8% | $-73.6M | $-70.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-17.1M | $-16.7M | $— | — |
| Q2 null | $1.1M | 60.3% | $-19.0M | $-17.2M | $— | — |
| Q1 null | $742.0K | 37.5% | $-17.2M | $-16.2M | $— | — |
| Q4 2023 | $1.5M | 69.4% | $-13.0M | $-12.0M | $-0.33 | — |